INTRODUCTION
Launch Date: December 13, 2021
ACPE Release Date: December 13, 2021
Expiration Date: November 30, 2022
TARGET AUDIENCE
This educational activity is strictly for healthcare providers who are involved in the clinical care of
patients with pulmonary arterial hypertension including physicians, physician assistants, registered
nurses, nurse practitioners, and pharmacists.
LEARNING OBJECTIVES
Upon completion of this enduring material, participants should be better able to:
METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT
- There are no fees for participating in and receiving credit for this enduring material.
- Review the learning objectives and activity information
- Review all modules associated with this activity
- Successfully complete the post-test ( accuracy or better)
- Complete the online evaluation
- The estimated time to complete this enduring material is hour(s)
- Upon successful completion, your AMA or ANCC certificate will be emailed to you. ACPE credit will be submitted to Duquesne University and posted to CPE Monitor.
ACCREDITATION STATEMENTS
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Practice Point Communications, Inc. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for ANCC contact hour. Nurses should only claim credit for the actual time spent participating in the activity.
PHARMACISTS
This knowledge-based activity is accredited for hour of continuing pharmacy education (CPE) credit. Duquesne University School of Pharmacy will report all credit to CPE Monitor after receiving evidence of successful completion of the course (must be within 30 days of the date the learner engaged in the CE activity). Successful completion includes achieving a score of at least 80% on the test and a completed evaluation.
Duquesne University School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (
). Participation in the entire knowledge-based activity is required to obtain a certificate. This activity is being presented without bias and with commercial support.
Effective January 1, 2012, all pharmacists are required to provide their NABP e-Profile ID # and Date of Birth (in MMDD format) for issuance of CE credits for any ACPE-accredited CPE sessions. Please go to the following website for full details:
https://nabp.pharmacy/cpe-monitor-service.
DISCLOSURE INFORMATION
In compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, it is the policy for all accreditors of this accredited continuing education activity as named above to ensure accuracy, balance, objectivity, independence, and scientific rigor in all their educational activities, and to commit to protecting learners from promotion, marketing, and commercial bias. All faculty, planners and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. This enduring material may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of the accredited providers and Practice Point Communications.
DISCLOSURES
The accredited providers have mitigated and are disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:
PLANNING COMMITTEE DISCLOSURE INFORMATION
Karim El-Kersh, MD
Speaker Bureau: United Therapeutics
Consultant: Acceleron
Advisory Boards/Sponsored Research: Actelion, United Therapeutics
Nothing to disclose
UNMC: Valeta Creason-Wahl, Heidi Keeler, PhD, RN; Renee Paulin, MSN, RN, CWOCN; Brenda Ram, CMP, CHCP
DU: Amy G. Woods, PharmD, MS Leadership
PPC: Bronwyn Boyes, Ashley Richardson; Julia Peterson
FACULTY DISCLOSURES
Ronald Oudiz, MD
Industry funded research/investigator: AADi bioscience, Actelion/Johnson & Johnson, Liquidia, United Therapeutics
Speakers Bureau, Faculty, Peer Reviewer: Actelion/Johnson & Johnson, United Therapeutics
Advisory Committee/Board: AADi bioscience, Acceleron, Actelion/Johnson & Johnson, Liquidia, Medtronic, United Therapeutics
Dunbar Ivy, MD
Industry funded research/investigator: Actelion/Janssen, Bayer, GSK, Gossamer, Lilly, United Therapeutics, PepPH Association
Advisory Committee/Board: Actelion/Janssen, Bayer, GSK, Gossamer, Lilly, United Therapeutics, PepPH Association
Consultant: Actelion/Janssen, Bayer, GSK, Gossamer, Lilly, United Therapeutics, PepPH Association
Honoraria: Actelion/Janssen, Bayer, GSK, Gossamer, Lilly, United Therapeutics, PepPH Association
Marc Humbert, MD, PhD
Consultant: Acceleron, Merck, Janssen
PRIVACY POLICY
The University of Nebraska Medical Center, Duquesne University School of Pharmacy, and Practice Point Communications protect the privacy of personal and other information regarding participants and educational collaborators. The University of Nebraska Medical Center, Duquesne University School of Pharmacy, and Practice Point Communications will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME, ANCC, or ACPE.
The University of Nebraska Medical Center, Duquesne University School of Pharmacy, and Practice Point Communications maintain physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.
COPYRIGHT INFORMATION
Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software (“Materials”) found on the site subject to the following terms, conditions, and exceptions:
The Materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without prior written permission.
HARDWARE/SOFTWARE REQUIREMENTS
Computer:
- Hardware: A minimum of 512MB of RAM and a Pentium IV CPU for Intel-based hardware & PowerPC G4 or above for MAC.
- Graphics/Monitor: A color monitor capable of a minimum of 1024 x 768 pixel resolution.
- Network: An Internet connection with 1Mbps available download & 256kbps bandwidth.
Software/Browser:
- Windows 7 or above running Internet Explorer 10 or above.
- MAC OSX 10.5 (Leopard) or above running Safari 6 or above, or any version of Chrome, Firefox or Opera published in the last two years.
- A recent version of a Linux distribution or FreeBSD running Chrome v13, Opera 11.5, Firefox 5.0.1, or Epiphany 3.0.4 or above.
Mobile Device:
- Any Apple iPad or iPad Mini running iOS 7.1 or above.
- Android tablets such as the Kindle Fire or Samsung Galaxy S.
COMMERCIAL SUPPORT ACKNOWLEDGMENT
Supported by independent educational grants from United Therapeutics Corporation, Bayer U.S.
and Actelion Pharmaceuticals U.S., Inc., A Janssen Pharmaceutical Company of Johnson & Johnson